Cornelia Emilia Zorca

Dr. Cornelia Emilia Zorca


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2018 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
FLFrédéric Lessard
Frédéric Lessard
SISebastian Igelmann
Sebastian Igelmann
CTChristian Trahan
Christian Trahan
GHGeneviève Huot
Geneviève Huot
ESEmmanuelle Saint-Germain
Emmanuelle Saint-Germain
Gerardo FerbeyreGerardo Ferbeyre
Gerardo Ferbeyre

1 April 2014 in Molecular Cell
Verified
Journal Article
Closed access
LKLark Kyun Kim
Lark Kyun Kim
EEEnric Esplugues
Enric Esplugues
CZCornelia Emilia Zorca
Cornelia Emilia Zorca
FPFabio Parisi
Fabio Parisi
YKYuval Kluger
Yuval Kluger
RFRichard A. Flavell
Richard A. Flavell

31 May 2006 in Nucleic Acids Research
Verified
Journal Article
Open access
SGSander Granneman
Sander Granneman
CLChieYu Lin
ChieYu Lin
ECErica A Champion
Erica A Champion
MNMadhusudan R Nandineni
Madhusudan R Nandineni
CZCornelia Emilia Zorca
Cornelia Emilia Zorca
SBSusan Baserga
Susan Baserga
While 18 putative RNA helicases are involved in ribosome biogenesis in Saccharomyces cerevisiae, their enzymatic properties have remained largely biochemically uncharacterized. To better understand their function, we examined the enzymatic properties of Dpb8, a DExD/H box protein previously shown to be required for the synthesis of the 18S rRNA. As expected for an RNA helicase, we demonstrate that recombinant Dbp8 has ATPase activity in vitro, and that this activity is dependent on an intact ATPase domain. Strikingly, we identify Esf2, a nucleolar putative RNA binding protein, as a binding partner for Dbp8, and show that it enhances Dbp8 ATPase activity by decreasing the K(M) for ATP. Thus, we have uncovered Esf2 as the first example of a protein co-factor that has a stimulatory effect on a nucleolar RNA helicase. We show that Esf2 can bind to pre-rRNAs and speculate that it may function to bring Dbp8 to the pre-rRNA, thereby both regulating its enzymatic activity and guiding Dbp8 to its site of action.

8 October 2024 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
ABArmin Bayati
Armin Bayati
RARiham Ayoubi
Riham Ayoubi
AAAdriana Aguila
Adriana Aguila
CZCornelia Emilia Zorca
Cornelia Emilia Zorca
GDGhislaine Deyab
Ghislaine Deyab
PMPeter S. McPherson
Peter S. McPherson

8 December 2016 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
SRSamir Rahman
Samir Rahman
CZCornelia Emilia Zorca
Cornelia Emilia Zorca
TTTatiana Traboulsi
Tatiana Traboulsi
ENEmmanuel Noutahi
Emmanuel Noutahi
MKMatthew R. Krause
Matthew R. Krause
DZDaniel Zenklusen
Daniel Zenklusen
Enhancers are intergenic DNA elements that regulate the transcription of target genes in response to signaling pathways by interacting with promoters over large genomic distances. Recent studies have revealed that enhancers are bi-directionally transcribed into enhancer RNAs (eRNAs). Using single-molecule fluorescence in situ hybridization (smFISH), we investigated the eRNA-mediated regulation of transcription during estrogen induction in MCF-7 cells. We demonstrate that eRNAs are localized exclusively in the nucleus and are induced with similar kinetics as target mRNAs. However, eRNAs are mostly nascent at enhancers and their steady-state levels remain lower than those of their cognate mRNAs. Surprisingly, at the single-allele level, eRNAs are rarely co-expressed with their target loci, demonstrating that active gene transcription does not require the continuous transcription of eRNAs or their accumulation at enhancers. When co-expressed, sub-diffraction distance measurements between nascent mRNA and eRNA signals reveal that co-transcription of eRNAs and mRNAs rarely occurs within closed enhancer–promoter loops. Lastly, basal eRNA transcription at enhancers, but not E2-induced transcription, is maintained upon depletion of MLL1 and ERα, suggesting some degree of chromatin accessibility prior to signal-dependent activation of transcription. Together, our findings suggest that eRNA accumulation at enhancer–promoter loops is not required to sustain target gene transcription.

2 July 2022 in Cells
Verified
Journal Article
Open access
PDF file
GTGOIRAN Thomas
GOIRAN Thomas
MEMohamed Eldeeb
Mohamed Eldeeb
CZCornelia Emilia Zorca
Cornelia Emilia Zorca
EFEdward A. Fon
Edward A. Fon
The best-known hallmarks of Parkinson’s disease (PD) are the motor deficits that result from the degeneration of dopaminergic neurons in the substantia nigra. Dopaminergic neurons are thought to be particularly susceptible to mitochondrial dysfunction. As such, for their survival, they rely on the elaborate quality control mechanisms that have evolved in mammalian cells to monitor mitochondrial function and eliminate dysfunctional mitochondria. Mitophagy is a specialized type of autophagy that mediates the selective removal of damaged mitochondria from cells, with the net effect of dampening the toxicity arising from these dysfunctional organelles. Despite an increasing understanding of the molecular mechanisms that regulate the removal of damaged mitochondria, the detailed molecular link to PD pathophysiology is still not entirely clear. Herein, we review the fundamental molecular pathways involved in PINK1/Parkin-mediated and receptor-mediated mitophagy, the evidence for the dysfunction of these pathways in PD, and recently-developed state-of-the art assays for measuring mitophagy in vitro and in vivo.